Gelato and Mastorino, in their analysis of a patient who developed multiple sclerosis (MS) after starting dupilumab treatment for atopic dermatitis, hypothesized that dupilumab could induce a shift toward Th1/Th17 polarization by blocking the shared receptor subunit for IL-4 and IL-13. Here, IL4 is linked to myeloid sarcoma.